CV 205-502 in acromegaly

Area of Science:

• Endocrinology
• Pharmacology
• Internal Medicine

Background:

• Acromegaly is a disorder caused by excessive growth hormone (GH) production.
• Dopamine agonists are used to manage acromegaly by suppressing GH and prolactin (PRL).
• CV 205-502 is a new long-acting dopamine agonist evaluated for acromegaly treatment.

Purpose of the Study:

• To evaluate the effects of the novel dopamine agonist CV 205-502 on GH, IGF-I, and PRL levels in acromegalic patients.
• To compare the efficacy and duration of action of CV 205-502 with bromocriptine.

Main Methods:

• An open study involving acromegalic patients.
• Acute administration of CV 205-502 (0.0375 mg, orally) to assess immediate effects.
• Chronic treatment with CV 205-502 (0.150-0.600 mg/day) for up to 12 months.
• Retrospective comparison with prior bromocriptine treatment data.

Main Results:

• Acute CV 205-502 administration did not alter GH but significantly decreased PRL for 24 hours.
• Chronic CV 205-502 treatment significantly reduced GH and IGF-I levels (p < 0.05).
• The GH-lowering effect was similar to bromocriptine but more prolonged.
• No bromocriptine-resistant patients responded to CV 205-502.

Conclusions:

• Chronic CV 205-502 treatment effectively lowers GH and PRL in acromegaly.
• The drug's effect is comparable to bromocriptine but offers a longer duration of action.
• CV 205-502 may achieve normal GH/IGF-I levels in some patients, but it is ineffective in bromocriptine-resistant cases.